Results 261 to 270 of about 790,770 (284)

Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1)

Preparative Biochemistry & Biotechnology, 2019
Targeting the interaction interface is an effective strategy to obtain programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-L1) nanobody blockers. To validate this strategy, the interaction interface between PD-1 and the PD-L1 extracellular domain were analyzed using Cn3D 4.1. The peptide PD-1125-136 located at the interface of PD-1 was selected as the
Biyan, Wen, Lin, Zhao, Yuchu, Wang, Chuangnan, Qiu, Zhimin, Xu, Kunling, Huang, He, Zhu, Zemin, Li, Huangjin, Li   +8 more
openaire   +2 more sources

Molecular Imaging of PD-1 Unveils Unknown Characteristics of PD-1 Itself by Visualizing “PD-1 Microclusters”

Programmed cell death-1 (PD-1) is one of the most famous coinhibitory receptors that are expressed on effector T cells to regulate their function. The PD-1 ligands, PD-L1 and PD-L2, are expressed by various cells throughout the body at steady state and their expression was further regulated within different pathological conditions such as tumor-bearing
Wataru, Nishi, Ei, Wakamatsu, Hiroaki, Machiyama, Ryohei, Matsushima, Yosuke, Yoshida, Tetsushi, Nishikawa, Hiroko, Toyota, Masae, Furuhata, Hitoshi, Nishijima, Arata, Takeuchi, Makoto, Suzuki, Tadashi, Yokosuka   +11 more
openaire   +2 more sources

Glucocorticoids and PD-1

Science Signaling, 2018
Signaling by the glucocorticoid receptor in NK cells induces expression of the checkpoint inhibitor PD-1 to prevent immunopathology.
openaire   +1 more source

Targeting PD-1

Science Signaling, 2018
Loss of an E3 ubiquitin ligase that targets PD-1 for degradation leads to inefficient antitumor responses by T cells.
openaire   +1 more source

Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors

Melanoma Research
The aim of this study was to determine whether the pretreatment CD8+PD-1+ to CD4+PD-1+ (PERLS) ratio is an independent risk prognostic factor of advanced melanoma patients. We retrospectively analyzed the efficacy and flow cytometry data from advanced melanoma patients who received PD-1 inhibitor as monotherapy between January 1, 2018 and January 26 ...
Yao, Gao, Yao, Wang, Yueyue, Luo, Yong, Zhang, Saiqi, Wang, Xiance, Tang, Peng, Qin, Benling, Xu, Quanli, Gao, Tiepeng, Li   +9 more
openaire   +2 more sources

FBXO38 Drives PD-1 to Destruction

Trends in Immunology, 2019
Aberrant expression of T cell-resident programmed cell death protein-1 (PD-1) is known to promote tumor progression. A recent study (Nature 2018;564:130-135) has now identified the E3 ubiquitin ligase FBXO38 as a crucial regulator of PD-1 protein turnover in T cells, providing a novel mechanism for potential use in cancer immunotherapy.
Taryn M, Serman, Michaela U, Gack
openaire   +2 more sources

Reactions of iodobenzene on Pd(1 1 1) and Pd(1 1 0)

Applied Surface Science, 2003
Abstract We have investigated the formation and reaction of phenyl fragments on Pd(1 1 1) and Pd(1 1 0), using synchrotron radiation-based photoelectron spectroscopy. The phenyl fragments are formed by carboniodine bond scission of iodobenzene, taking place already at 80 K. Pd(1 1 0) is seen to be more reactive than Pd(1 1 1) in this reaction.
H. von Schenck, J. Weissenrieder, S. Helldén, B. Åkermark, M. Göthelid   +4 more
openaire   +1 more source

Tug of war with anti–PD-1

Science, 2017
Cancer Antibodies against immune checkpoint proteins such as programmed cell death 1 (PD-1) are gaining increasing prominence in cancer treatment, but these promising therapeutics do not always work. To be effective in preventing T cells from becoming exhausted, antibodies against PD-1 must remain bound to the T cells. Arlauckas et al.
openaire   +2 more sources

PD-1/PD-L1 in Disease

Immunotherapy, 2017
Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor ...
Kuol, Nyanbol, Stojanovska, Lily, Nurgali, Kulmira, Apostolopoulos, Vasso   +3 more
openaire   +3 more sources

Role of PD-1 in Immunity and Diseases

2017
Immunity developed to defend our bodies from foreign particles, including bacteria and viruses. Although effector cells responsible for acquired immunity, mainly T cells, and B cells, are able to distinguish self from non-self, they sometimes attack the body's tissues because of imperfect central tolerance.
Kenji, Chamoto, Muna, Al-Habsi, Tasuku, Honjo   +2 more
openaire   +2 more sources